Assessment of the Efficacy and Safety of Ivy Leaf (Hedera helix) Cough Syrup Compared with Acetylcysteine in Adults and Children with Acute Bronchitis

Table 4

Relevant concomitant diseases and treatments.

Concomitant infections and other diseases	EA 575®	ACC	Total	value
No (N; %)	66; 55.9%	13; 61.9%	79; 56.8%	NS
Yes (N; %)	54; 44.1%	6; 38.1%	60; 43.2%
Total	118; 100.0%	21; 100.0%	139; 100.0%
Yes, namely
Bronchial asthma	8; 6.8%	0; 0%	8; 5.8%	NS
Otitis media	4; 3.4%	0; 0%	4; 2.9%	NS
Rhinosinusitis	13; 11.0%	2; 9.5%	15; 10.8%	NS
Other chronic respiratory diseases	4; 3.4%	1; 4.8%	5; 3.6%	NS
Allergies	4; 3.4%	0; 0%	4; 2.9%	NS
Inflammation of upper resp. tract	21; 17.8%	3; 14.3%	24; 17.3%	NS
	EA 575®	ACC	Total	-value
Treatment of concomitant diseases
None (N; % of patient within treatment group)	8; 6.8%	0; 0.0%	8; 5.8%	NS
Antibiotic treatment	22; 18.6%	3; 14.3%	25; 18.0%	NS
Other treatment (N; %)	23; 19.5%	8; 38.1%	31; 22.3%	NS

^∗Chi-squared test; NS = not significant (e.g., ); N = number of subjects.